Re: Trial

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Trial

in response to

Re: Trial

Hartland

posted on Sep 19, 2016 11:25AM

I am not claiming to be an expert in the 3 + 3 dose escalation design. However, it is my understanding that when the current patient/dose combo (patient set A on dose A) clears the safety screen, then 3 more patients (patient set B) are added to the next highest dose (dose B) and the previous 3 patients (patient set A) stay on their current dose A. I think, but I'm not entirely sure, that when patient set B subsequently clears their safety screen after 4 weeks on dose B, that patient set A can then move up to dose B as well.